• image

Registered Medicines

  • Salofalk
  • Ursofalk

Salofalk® Granules have been specially developed for the oral treatment of ulcerative colitis which always affects the distal colon. The release characteristics of Salofalk® Granules are fundamentally different from those of Salofalk® Tablets and other mesalazine preparations.

Salofalk® Granules have a patented dual release technology, which comprises an Eudragit coating which dissolves at a pH value above 6, and a matrix core for controlled, sustained release (see image). This enables consistent concentrations of mesalazine to be distributed throughout the entire colon, including the rectum, making Salofalk® Granules ideal for the treatment of both distal and more extensive ulcerative colitis.

saloflak granules 6 4


URSOFALK (Capsules)


Each capsule contains 250 mg ursodeoxycholic acid as the active ingredient

Inactive ingredients:
Colloidal anhydrous silica, magnesium stearate, maize starch, purified water and a gelatin capsule.

For the treatment of a disease called primary biliary cirrhosis (PBC), provided there is no complications of the liver, called cirrhosis.


Do not use URSOFALK if:
•    You are allergic to the active ingredient or to any of the other ingredients.
•    You suffer from inflammation or blockage of the gall bladder or biliary tract.
•    You are pregnant or planning to become pregnant.
•    You suffer from stomach ulcers.
•    You suffer from certain bowel diseases.

Pregnancy and Breast-feeding:
If you are pregnant or breast feeding your baby while taking URSOFALK please consult your doctor, pharmacist or other health care professional for advice. Do not take URSOFALK if you are pregnant or breastfeeding.

Tell your doctor or pharmacist if any of the following apply to you:
-    You are pregnant or planning to become pregnant.